The ARTEMIS-011 phase III trial, run by GSK's partner Hansoh Pharma in China, met its primary endpoint, with risvutatug rezetecan showing a statistically significant improvement in progression-free survival over chemotherapy in relapsed osteosarcoma. The results will support a regulatory submission by Hansoh in China.

What was announced

GSK plc (LSE:GSK) said on 26 October 2026 that ARTEMIS-011, a pivotal phase III, multicentre, randomised, open-label trial in China, met its primary endpoint. The trial tested risvutatug rezetecan, known as Ris-Rez, an investigational antibody-drug conjugate targeting B7-H3, in patients with relapsed or progressed osteosarcoma who had received at least two prior lines of systemic therapy.

The trial is sponsored by Hansoh Pharmaceutical Group, which licensed Ris-Rez to GSK (LSE:GSK). GSK holds exclusive rights outside mainland China, Hong Kong, Macau and Taiwan. The data were presented as a late-breaking abstract in a Presidential Symposium at the ESMO Congress 2026.

Patients were randomised 1:1 to Ris-Rez at 12.0 mg/kg every three weeks or to chemotherapy with gemcitabine (1,000 mg/m² on days 1 and 8) plus docetaxel (75 mg/m² on day 8) every three weeks. The release does not state how many patients were enrolled. GSK said the 12 mg/kg dose was chosen over the 8 mg/kg used in the ARTEMIS-008 small-cell lung cancer trial to account for the potential difficulty of penetrating bone tissue.

The numbers

The primary endpoint was progression-free survival (PFS) assessed by an independent review committee. GSK said Ris-Rez delivered a statistically significant and clinically meaningful improvement in PFS versus chemotherapy, with a hazard ratio of 0.33 (95% CI 0.20–0.55; p<0.0001), equivalent to a 67% reduction in the risk of disease progression or death.

At a median follow-up of 7.1 months, median PFS was 5.5 months with Ris-Rez compared with 1.4 months with chemotherapy. Secondary endpoints include investigator-assessed overall survival and PFS, objective response rate, disease control rate, duration of response and safety, but the release gives no results for overall survival or response rates.

Grade 3 or higher treatment-related adverse events occurred in 93% of patients on Ris-Rez and 83% on chemotherapy, with haematologic events the most common in both arms. Treatment-related adverse events led to discontinuation in 4% of Ris-Rez patients and 2% of chemotherapy patients. GSK said the safety findings were consistent with previous findings in this tumour type.

Background

Osteosarcoma is a rare cancer, with a global incidence of about 3.4 cases per million people per year, according to the release. GSK said that after first-line chemotherapy, treatment options for relapsed patients are "severely limited" and there is "no clear standard of care available."

Hesham Abdullah, Senior Vice President and Global Head of Oncology, R&D at GSK, said: "For patients with relapsed osteosarcoma, where treatment options are extremely limited, these findings are particularly important." Lu Xie, Deputy Medical Director of the Musculoskeletal Tumor Center and Clinical Associate Professor at Peking University, and the trial's principal investigator, said the PFS improvement "adds important new evidence in a setting where advances have been difficult to achieve."

Ris-Rez holds US Breakthrough Therapy Designation for relapsed or refractory osteosarcoma. GSK said more than 1,000 patients have received the drug across its EMBOLD programme.

What to watch next

The immediate next step is Hansoh's planned regulatory submission in China, for which no timetable is given. Outside China, GSK is running EMBOLD Sarcoma-202, a global phase Ib/II trial in previously treated advanced or metastatic sarcomas, including osteosarcoma.

The wider programme includes phase III trials in late-line extensive-stage small-cell lung cancer and metastatic castration-resistant prostate cancer, with further phase III studies planned in early-line small-cell lung cancer and chemotherapy-naïve prostate cancer. Investors will look for overall survival and response data from ARTEMIS-011, as well as any read-across to GSK's own development plans in sarcoma.